Brand vs Compounded GLP-1: What to Know in 2026

Brand and compounded GLP-1s can contain the same active molecule, but they are not the same product. Brand versions like Ozempic/Wegovy (semaglutide) and Mounjaro/Zepbound (tirzepatide) are FDA-approved, standardized, and dispensed in prefilled pens. Compounded versions are made by pharmacies, are not FDA-approved as finished products, and usually come as vials you draw with a syringe. The 2025 resolution of the official shortage changed which compounded products are permitted, so the 2026 picture is different from prior years and is still evolving.

This article explains the practical differences in oversight, consistency, cost, and tracking, and where the regulatory line sits as of mid-2026. It is general education, not medical or legal advice, and it does not endorse any particular way of sourcing medication. Always confirm what you are taking with your prescriber and pharmacist.

What is a compounded GLP-1, exactly?

A compounded medication is one prepared by a pharmacy for a specific patient or in batches, rather than manufactured and packaged by the original drugmaker. In the United States, compounding happens at two kinds of facilities: 503A state-licensed pharmacies, which compound for individual prescriptions, and 503B outsourcing facilities, which can produce larger batches under stricter federal oversight.

Compounded semaglutide and tirzepatide became widely available during the official drug shortages. When the FDA declares a drug in shortage, compounders are allowed, under enforcement discretion, to produce copies of the commercially unavailable product. Semaglutide was declared in shortage in 2022, and tirzepatide followed.

The key thing to understand is that "compounded" is not a synonym for "generic." A generic is an FDA-approved copy that has cleared the agency's review. A compounded GLP-1 has not been through that approval process as a finished product, even when the underlying drug substance is the same molecule.

Brand vs compounded GLP-1, side by side

The table below lays out the practical differences. Treat it as a framework for a conversation with your clinician, not a recommendation toward either column. Regulatory details in particular continue to change.

Factor	Brand GLP-1	Compounded GLP-1
FDA status	Approved finished product; reviewed for safety, efficacy, and manufacturing quality	Not FDA-approved as a finished product; prepared by a pharmacy
Dosing format	Prefilled pen, dose displayed in mg; unit math not needed	Usually a multi-dose vial drawn in units on an insulin syringe
Strength consistency	Standardized concentration per the label	Concentration varies by pharmacy; same unit reading can mean different mg
Labeling	Standardized FDA-approved labeling and patient information	Varies by compounder; may add other ingredients (for example B vitamins)
Oversight	Full manufacturer quality systems and FDA inspection	503A state board oversight or 503B federal oversight; less standardized
Cost	Generally higher list price; insurance coverage varies	Historically lower cash-pay price; availability shifted after 2025
Availability in 2026	Commercially available	Broad compounding no longer permitted post-shortage; limited individualized use may remain
Tracking complexity	Lower; dial a dose	Higher; you must log concentration plus units and mg per vial

Sources: FDA statements on compounding and GLP-1 supply; FDA shortage-resolution announcements (2024 to 2025); brand prescribing information for Ozempic, Wegovy, Mounjaro, and Zepbound.

The regulatory status in 2026 (read this carefully)

This is the part that changed most, and it is worth being precise. The shortages that justified broad compounding have been declared resolved.

The FDA confirmed the semaglutide shortage was resolved on February 21, 2025. Enforcement discretion for 503A pharmacies ended April 22, 2025, and for 503B outsourcing facilities on May 22, 2025. For tirzepatide, the shortage was declared resolved on December 19, 2024, with 503A facilities required to cease by February 18, 2025 and 503B facilities by March 19, 2025.

The practical result, as of mid-2026, is that broad commercial compounding of semaglutide and tirzepatide injections is no longer permitted under the shortage provisions. Some limited individualized compounding may still occur where a prescriber documents a specific clinical need, but the large-scale cash-pay compounded market that existed during the shortage has contracted significantly.

A fair word of caution for readers: the regulatory landscape here continues to evolve, and details can differ by state and by the type of facility involved. Anything you read about compounded GLP-1 availability has a short shelf life. Verify the current status with your prescriber or pharmacist rather than relying on a snapshot.

Safety and consistency: where the real differences sit

The biggest functional difference between brand and compounded is consistency. A brand pen delivers a known dose at a known concentration every time, with FDA-reviewed manufacturing behind it. A compounded vial's concentration is set by the compounding pharmacy and can differ from one source to another.

That concentration variability is the core safety issue. Because compounded vials are dosed in units on an insulin syringe, the same unit reading translates to a different milligram dose depending on the vial's concentration. The FDA has flagged dosing errors as a real-world risk with compounded GLP-1s, including cases where patients drew far more than intended.

None of this means compounded products are inherently dangerous or that brand products are immune to error. It means the margin for confusion is wider with compounded vials, which is exactly why unit-versus-mg literacy matters more there. Our guide on GLP-1 units, mL, and mg explained walks through what those numbers mean so you do not have to do risky math at the kitchen counter.

What is actually in a compounded vial

A second consideration is composition. During the shortage, a large share of compounded GLP-1 prescriptions did not just copy the brand drug; they added supplemental ingredients, commonly B vitamins, to differentiate the product. Some used salt forms of the active ingredient (such as semaglutide acetate or sodium) rather than the base form in the brand product.

These additions and variations are part of why compounded products are not interchangeable with the approved drug, and why the FDA has scrutinized them. An added vitamin may sound harmless, but it means you are taking a formulation that has not been studied as a finished product, with a different ingredient list than the trials that generated the weight-loss data were built on. If you are considering or using a compounded product, knowing exactly what is in it (the active form, the concentration, and any added ingredients) is a reasonable thing to ask your pharmacist.

Cost and access

Cost was the headline reason many people used compounded GLP-1s during the shortage: cash-pay compounded versions were often priced well below brand list prices, and brand coverage through insurance has been inconsistent for weight management specifically. We cover the economics in detail in compounded vs brand GLP-1 cost.

The caveat is that the 2025 shortage resolution changed the access equation. With broad compounding curtailed, the low-cost compounded route that defined 2023 and 2024 is far less available in 2026. Pricing, coupons, and savings programs for brand products are a separate moving target worth checking directly with the manufacturer and your pharmacy.

It is also worth being honest that the cost gap was never a pure apples-to-apples comparison. A lower price on a compounded vial bought you a product without FDA approval behind it, with more dosing-error risk and a formulation that might differ from the studied drug. That does not make the savings illusory for people who genuinely could not afford the brand, but it does mean the price difference reflected a difference in oversight and standardization, not just markup. As you weigh cost, weigh what the lower number does and does not include.

The part that does not change: protect your muscle either way

Here is the thread that runs through every GLP-1 decision: the format and the source affect logistics and cost, but they do not change the body-composition math. Rapid weight loss on any GLP-1 carries a risk of losing lean mass alongside fat. Research suggests roughly 25 to 40 percent of total weight lost on these drugs can come from lean mass (which includes water and organ mass, not only skeletal muscle), per body-composition substudies of the STEP and SURMOUNT trials.

Whether you are on a brand pen or a compounded vial, the levers that protect muscle are identical: adequate protein, resistance training, and tracking body composition rather than just the scale. The full picture lives in our GLP-1 muscle loss complete guide.

This is also where consistent dose tracking pays off regardless of which route you take. Myo logs both brand pens and compounded vials in units and mg, so your dose record stays clean and unambiguous even if you switch between formats. Because that dose log sits right next to your protein, training, and lean-mass data, you can actually read whether your plan is working rather than guessing. Myo is a tracking and education tool, not medical advice, and it is not affiliated with any GLP-1 maker.

How to decide

This is a prescriber conversation, not a do-it-yourself call. A few honest prompts to bring to that conversation:

Ask what is actually available to you now, given the post-shortage rules in your state. Ask about cost with and without insurance for the brand product, and whether any savings program applies. If a compounded option is still on the table for a documented clinical reason, ask about the exact concentration and how to dose and track it safely. And whatever you choose, set up a clean dose log from day one so your record is solid.

The bottom line: brand and compounded GLP-1s differ most in oversight, consistency, and, in 2026, availability. The molecule may be the same, but the safety net, the dosing format, and the tracking burden are not. Choose with your clinician, verify the current regulatory status, and keep the muscle-protecting habits steady no matter which column you land in.

References

FDA policies on compounding GLP-1s and supply stabilization: FDA drug alerts and statements, "FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize."

Semaglutide shortage resolved February 21, 2025; 503A enforcement discretion ended April 22, 2025; 503B ended May 22, 2025: FDA announcements; McDermott Will and Emery analysis.

Tirzepatide shortage resolved December 19, 2024; 503A ceased February 18, 2025; 503B ceased March 19, 2025: FDA announcements; NCPA summary.

Brand product details (semaglutide and tirzepatide): Ozempic, Wegovy, Mounjaro, and Zepbound prescribing information (accessdata.fda.gov).

Lean-mass share of weight lost on GLP-1s (~25-40%): SURMOUNT-1 body-composition substudy (DOM 2025, doi:10.1111/dom.16275); STEP 1 and SUSTAIN 8 DXA analyses.